Ventripoint's VMS+ (TM) 4.0 Submitted for Regulatory Approval in China by Lishman Global Inc.

Toronto, Canada – TheNewswire - April 28, 2026 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSX-V:VPT, OTC:VPTDF), is proud to announce that its strategic partner, Lishman Global Inc., has formally submitted Ventripoint's VMS+™ 4.0 system to China's National Medical Products Administration (NMPA), commonly referred to as the Chinese FDA, for regulatory approval. Importantly, Lishman Global has qualified for the NMPA's “green channel” pathway, an expedited review process designed to accelerate the approval of innovative medical technologies that address significant clinical needs. This designation is expected to streamline the regulatory timeline and facilitate faster access to the Chinese market.